Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Living Cell Technologies ( (AU:1AI) ) has provided an update.
Algorae Pharmaceuticals has updated its Securities Trading Policy in compliance with ASX Listing Rule 12.10, ensuring high standards of corporate conduct and market confidence. This update aims to prevent insider trading and misuse of unpublished information, thereby protecting the company’s reputation and integrity in securities dealings.
More about Living Cell Technologies
Algorae Pharmaceuticals is an AI-enabled pharmaceutical development company focused on pioneering drug synergy discovery and development for unmet medical needs. Utilizing its proprietary AI platform, AlgoraeOS, the company applies machine learning and deep neural networks to identify synergistic drug combinations with transformative therapeutic potential. Algorae collaborates with research institutions and pharmaceutical partners to accelerate the translation of AI-predicted therapies into clinical settings, aiming to expand its therapeutic pipeline and address unmet medical needs.
Average Trading Volume: 10,231,180
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.5M
For a thorough assessment of 1AI stock, go to TipRanks’ Stock Analysis page.